ABSTRACT
Patients with therapy-refractory or high-risk relapsed classical Hodgkin lymphoma are typically treated with the high-dose chemotherapy and autologous stem cell transplantation (HDC/ASCT) to consolidate the response to salvage therapy. The combination of brentuximab vedotin with gemcitabine has recently been shown to be an effective and safe salvage regimen. While the majority of patients with complete responses to this regimen ultimately underwent HDC/ASCT consolidation, four subjects, reported herein, achieved durable complete remissions lasting more than 4 years after the study treatment but without ASCT consolidation. Further investigation of treatment strategies incorporating targeted agents may allow omission of HDC/ASCT for select patients.
Subject(s)
Hematopoietic Stem Cell Transplantation , Hodgkin Disease , Immunoconjugates , Antineoplastic Combined Chemotherapy Protocols/adverse effects , Brentuximab Vedotin , Child , Deoxycytidine/analogs & derivatives , Hodgkin Disease/drug therapy , Hodgkin Disease/pathology , Humans , Immunoconjugates/therapeutic use , Neoplasm Recurrence, Local/drug therapy , Salvage Therapy , Stem Cell Transplantation , Transplantation, Autologous , GemcitabineABSTRACT
We present an 11-year-old girl with acute myelogenous leukemia and hemoptysis from abscess erosion into the descending thoracic aorta. We report a pediatric case of an aortobronchial fistula treated with an aortic endograft and discuss the technical limitations and potential complications of this procedure.